TITLE

Systemic therapy approved to treat cutaneous lymphoma

AUTHOR(S)
Thompson, Cheryl A.
PUB. DATE
December 2009
SOURCE
American Journal of Health-System Pharmacy;12/15/2009, Vol. 66 Issue 24, p2150
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the approval by the U.S. Food and Drug Administration to market the romidepsin or Istodax drugs of Gloucester Pharmaceuticals Inc. It notes that the drug will be used to treat cutaneous T-cell lymphoma (CTCL) in patients who have already underwent phototherapy. It also states that the drug is being administered via infusion over four hours on days 1, 8, and 15 of a 28-day cycle. Details related to the labeling of the new drug is provided.
ACCESSION #
46822528

 

Related Articles

  • Celgene's Purchase of Gloucester Puts a Scare in Allos Investors. Young, Donna // BioWorld Today;12/8/2009, Vol. 20 Issue 235, p1 

    The article reports on the proposed acquisition of Gloucester Pharmaceuticals Inc. by hematology cancer therapy provider Celgene Corp. Gloucester reportedly gained approval from the U.S. Food and Drug Administration (FDA) for its deacetylase inhibitor Istodax as a therapy for previously treated...

  • FDA Actions. Elliott, William T. // Clinical Oncology Alert;Jan2010 Supplement 2, p2 

    The article presents an update on drug approvals granted by the U.S. Food and Drug Administration (FDA), as of January 2010. A capsaicin patch to be manufactured by Lohmann Therapie-Systems has been approved as a topical treatment for post-herpetic neuralgia. Romidepsin, a histone deacetylase...

  • Gloucester's lymphoma drug granted FDA fast track status.  // PharmaWatch: Cancer;November 2004, Vol. 3 Issue 11, p8 

    Reports that the United States Food and Drug Administration (FDA) has granted fast track status designation to Gloucester Pharmaceuticals' lead product, FK228 (depsipeptide), as monotherapy for cutaneous T-cell lymphoma patients. Statement of the FDA on the fast track designation.

  • FDA Actions.  // Primary Care Reports;Jan2010 Pharmacology, p2 

    The article offers information on the drugs approved by the U.S. Food and Drug Administration (FDA) as of January 2, 2010. The capsaicin 8% patch is a new topical treatment for post-herpetic neuralgia (PHN), to be manufactured by Lohmann Therapie-Systems and distributed by NeurogesX as Qutenza....

  • Folotyn.  // Formulary;Jan2010, Vol. 45 Issue 1, p4 

    The article presents information on a new molecular entity, Folotyn (pralatrexate injection), a folate analogue metabolic inhibitor which was approved by the U.S. Food and Drug Administration (FDA) in September 2009 for the treatment of patients with relapsed or refractory peripheral T-cell...

  • FDA approves pralatrexate for treatment of rare lymphoma. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;11/1/2009, Vol. 66 Issue 21, p1890 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved Pralatrexate (Folotyn) from Allos Therapeutics Inc. for peripheral T-cell lymphoma treatment. It mentions that Pralatrexate is the first drug approved by the FDA for the treatment of the rare disease which occurs...

  • FDA Grants Accelerated Approval of ISTODAX(r) As Treatment for Patients with Peripheral T-Cell Lymphoma Who Have Received at Least One Prior Therapy.  // Biomedical Market Newsletter;6/19/2011, p176 

    The article reports on the accelerated approval given by the U.S. Food and Drug Administration (FDA) to Celgene Corp.'s drug ISTODAX® as treatment for peripheral T-cell lymphoma (PTCL) in patients who had at least one prior therapy. It states that the said approval was based on the six-month...

  • FDA actions. Elliott, William T. // Primary Care Reports;Jun2012 Pharmacology Watch, p2 

    The article reports that the FDA has approved Avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction (ED), and requires a labeling change on finasteride which is a Merck's testosterone blocker.

  • Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals. Baker, Danial E. // Hospital Pharmacy;Jun2012, Vol. 47 Issue 6, p471 

    Several tables are presented which provide data related to drug approvals, subsmission, and labeling which include the new drugs being approved by the U.S. Food and Drug Administration (FDA) from March 17 to April 13, 2012, newly FDA-approved dosage forms and indications from March 17 to April...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics